DYADIC INTERNATIONAL INC DYAI

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

doing business as Dyadic Applied BioSolutions, is a global biotechnology company based in Jupiter, Florida, with operations in the United

States and a satellite office in the Netherlands. The Company develops, manufactures, and commercializes precision-engineered, animal-free

recombinant proteins and enzymes for applications in life sciences, food and nutrition, and bio-industrial markets. These products are

produced using Dyadic's proprietary microbial expression platforms, including the C1 and Dapibus™ systems, which enable scalable

Last close 0.40 2026-10-23
Market cap $14.5M 2026-06-30 share count
52-week range 0.34 - 1.60

Valuation FY2025 figures against the last close

P/S4.7x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.23

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $3.1M$3.5M$2.9M$2.9M$2.4M$1.6M$1.7M$1.3M$758.4K—
Cost of revenue $2.3M$1.2M$2.0M$2.1M$1.9M$1.4M$1.5M$1.0M$680.2K—
Gross profit $770.5K$2.3M$923.0K$807.1K$459.4K$177.0K$221.4K$268.2K$78.2K—
R&D $2.2M$2.0M$3.3M$4.5M$8.4M$3.9M$3.1M$2.1M$1.8M—
SG&A $5.8M$6.1M$5.8M$6.4M$6.7M$6.1M$5.5M$4.5M$5.0M—
Total operating expenses $10.3M$9.4M$11.1M$13.1M$17.1M$11.6M$11.0M$8.9M$7.9M—
Operating income -$7.2M-$5.9M-$8.2M-$10.2M-$14.7M-$10.0M-$9.3M-$7.6M-$7.1M—
Pre-tax income ————-$13.1M-$9.3M-$8.3M-$4.7M-$2.1M—
Income tax ————$0$31.3K$10.3K$1.0M$66.7K—
Net income -$7.4M-$5.8M-$6.8M-$9.7M-$13.1M-$9.3M-$8.3M-$5.7M-$2.1M—
EPS, basic -0.23-0.20-0.24-0.34-0.47—————
EPS, diluted -0.23-0.20——-0.47-0.34-0.31-0.21-0.07—
Shares, diluted (wtd. avg.) 32.6M29.3M28.8M28.4M——————

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $4.6M$6.5M$6.5M$5.8M$15.7M$20.6M$4.8M$2.4M$5.8M$14.3M
Short-term investments $2.7M$2.8M————————
Receivables $1.1M$237.0K$466.2K$330.0K$277.8K$294.2K$558.5K$318.7K$271.0K—
Total current assets $9.9M$9.8M$8.1M$13.4M$21.0M$29.8M$35.6M$42.7M$49.6M—
Total assets $9.9M$9.9M$8.2M$13.7M$21.3M$30.1M$37.5M$43.3M$50.7M—
Accounts payable $852.0K$482.3K$656.4K$1.3M$1.5M$1.0M$943.4K$309.1K$520.3K—
Total current liabilities $3.7M$2.4M$2.3M$2.4M$2.6M$1.6M$1.6M$849.6K$768.9K—
Total liabilities $8.7M$7.5M$2.3M$2.6M$2.9M$1.6M————
Retained earnings -$93.5M-$86.1M-$80.3M-$73.5M-$63.7M-$50.7M-$41.4M-$33.0M-$27.4M—
Total equity $1.2M$2.5M$5.9M$11.1M$18.4M$28.4M$35.9M$42.5M$50.0M$57.7M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$5.7M-$4.0M-$6.7M-$8.1M-$11.3M-$6.6M-$5.8M-$4.4M-$1.7M—
Stock-based compensation $930.2K$1.1M$1.2M$1.9M$1.8M$1.7M$1.2M$467.2K$643.4K—
Investing cash flow $82.1K-$1.9M$7.4M-$2.4M$5.2M$22.1M$7.7M$3.3M-$812.1K—
Financing cash flow $5.0M$5.8M$0$543.6K$1.2M$255.5K$550.2K-$2.3M-$6.2M—
Buybacks ——————$0$2.3M$6.2M$3.6M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-022505.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -15M -10M -5M 0 5M Revenue, FY2017: 758.4K Gross profit, FY2017: 78.2K Net income, FY2017: -2.1M Revenue, FY2018: 1.3M Gross profit, FY2018: 268.2K Net income, FY2018: -5.7M Revenue, FY2019: 1.7M Gross profit, FY2019: 221.4K Net income, FY2019: -8.3M Revenue, FY2020: 1.6M Gross profit, FY2020: 177K Net income, FY2020: -9.3M Revenue, FY2021: 2.4M Gross profit, FY2021: 459.4K Net income, FY2021: -13.1M Revenue, FY2022: 2.9M Gross profit, FY2022: 807.1K Net income, FY2022: -9.7M Revenue, FY2023: 2.9M Gross profit, FY2023: 923K Net income, FY2023: -6.8M Revenue, FY2024: 3.5M Gross profit, FY2024: 2.3M Net income, FY2024: -5.8M Revenue, FY2025: 3.1M Gross profit, FY2025: 770.5K Net income, FY2025: -7.4M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $758.4K $1.3M $1.7M $1.6M $2.4M $2.9M $2.9M $3.5M $3.1M
Gross profit — $78.2K $268.2K $221.4K $177.0K $459.4K $807.1K $923.0K $2.3M $770.5K
Net income — -$2.1M -$5.7M -$8.3M -$9.3M -$13.1M -$9.7M -$6.8M -$5.8M -$7.4M

Recent filings and events

  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Other event Item 8.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02
  • Delisting notice Item 3.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $237.48B 30.9x 10.0%
GILD GILEAD SCIENCES, INC. $193.48B 23.0x 2.4%
MRNA Moderna, Inc. $79.89B — -39.9%
RVMD Revolution Medicines, Inc. $40.08B — —
BIIB BIOGEN INC. $37.01B 28.5x 2.2%
EXEL EXELIXIS, INC. $15.99B 23.2x 7.0%
NBIX NEUROCRINE BIOSCIENCES INC $14.51B 30.6x 21.4%
HALO HALOZYME THERAPEUTICS, INC. $14.26B 49.1x 37.6%